Mark Kelly
@markkellyneuro.bsky.social
Neurology trainee and PhD candidate at Royal College of Surgeons in Ireland.
Not the Senator of Arizona...
Not the Senator of Arizona...
Reposted by Mark Kelly
🚨The LANTERN, the first patient-reported outcome measure for LGI1-ab autoimmune encephalitis, was co-designed by our researcher Dr Mark Kelly, Oxford Autoimmune Neurology Group and patients. It will be key in future trials and clinical care: onlinelibrary.wiley.com/doi/full/10....
Capturing what matters: Patient‐reported LGI1‐ANTibody encephalitis outcome RatiNg scale (LANTERN)
Background LGI1-antibody encephalitis (LGI1-Ab-E) is a common form of autoimmune encephalitis where most patients demonstrate ‘good’ clinician-rated outcomes. However, more targeted questionnaires r...
onlinelibrary.wiley.com
February 26, 2025 at 1:46 PM
🚨The LANTERN, the first patient-reported outcome measure for LGI1-ab autoimmune encephalitis, was co-designed by our researcher Dr Mark Kelly, Oxford Autoimmune Neurology Group and patients. It will be key in future trials and clinical care: onlinelibrary.wiley.com/doi/full/10....